Analysis of histological sections of disease tissues has traditionally relied on pathologist-based scoring. In an Advanced Online Publication in Nature Medicine Camp et al. describe techniques to ...
With respect to assay development, quality assurance and, ultimately, clinical adoption, the primary subject of this review, these advantages are critical. Implicit with these advantages, TMAs enable ...
Tissue microarray (TMA) technology has transformed colorectal cancer research by enabling simultaneous analysis of hundreds of tissue samples under uniform experimental conditions. In this approach, ...
To study tissue samples from multiple patients, researchers use tissue microarrays (TMAs), a technology in which hundreds of tissue cores are arranged on a single glass slide for analysis by ...
The Geniom® RT Analyzer, a new benchtop microarray processing instrument, was presented by febit at Select Bioscience’s “Advances in Microarray Technology”. The platform complements Geniom® One, the ...
Emphasis on Potential Clinical Applications and Enhancing RNA Sample Quality Researchers are beginning to look at tissue microarrays (TMA) from different perspectives, including one with a strong ...
Type A aortic dissection (TAAD) is a vascular disease with high mortality; however, the role of gene methylation in its pathogenesis has received little attention. This study aimed to identify ...
A ten-year study of 849 pregnancy loss samples demonstrates that chromosomal microarray testing detects genetic abnormalities in over sixty-two percent of cases, with risk rising steeply alongside ...
Pan-cancer analysis and KNSTRN as a potential prognosis biomarker. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract does not include a full text component.
EYSINS, Switzerland, April 3, 2025 /PRNewswire/ --Today, AliveDx announces it has submitted 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the MosaiQ AiPlex® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results